With multiple active patent applications, COMPASS is building on its leadership position in psilocybin therapy and mental health care Every patient has a unique story
After completing a successful IPO, Gain Therapeutics is already firming up its financial position Established in 2017 with the support of its founders and institutional
With significant clinical and regulatory precedents already established, Ocuphire Pharma is advancing quickly and preparing for upcoming milestones It’s practically inevitable: as we age, our
With a focus on patient access – and an army of high-powered sales professionals – Agile remains fully committed to women’s health, freedom, and flexibility
Building on the success of a significant core business, Rockwell Medical is setting a new standard for anemia patients and caregivers It’s a truly under-addressed
With Medicenna’s Supuerkine Program advancing rapidly, visionary therapies are within reach Clinical-stage immunotherapy company Medicenna Therapeutics Corp. is boldly pursuing medical therapies through proprietary tools
Scynexis’ broad-spectrum antifungal offers blockbuster potential, while the CEO’s major purchase signals shareholder confidence Few events offer truer insight into executive-level sentiment like insider buying
Driven by Passion, Windtree Therapeutics (WINT) Is Quickly Gaining Market Recognition With multiple clinical assets and first-in-class medical treatments, Windtree’s reaching one milestone after another
As Leap shores up its capital position and targets tumors with data-driven trials, LPTX stock could grow by leaps and bounds The onset of Covid-19
The time to consider BLU stock is now as BELLUS Health fast-tracks the clinical timeline In the biotechnology domain, the terms “life-changing” and “life-saving” are
Stockpence is currently seeking to expand our team of contributors. We’re looking for financial gurus & article writers to write about trending market news and investment ideas about the stock market.
If you’re interested please contact us!
Investing involves substantial risk. Neither the authors, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the articles herein. No reader should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, on any featured company here.
Some of the companies featured here may pay a fee to an affiliate of the publication to broaden awareness of said company.
The principals of the publication may buy or sell shares of the featured companies from time-to-time.
Join our free mailing list below to receive real-time news alerts and our next featured stock!
Investing involves substantial risk. Neither the Authors, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the articles herein. No reader should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, on any featured company here.
Some of the companies featured here may pay a fee to an affiliate of the publication to broaden awareness of said company.
The principals of the publication may buy or sell shares of the featured companies from time-to-time.
Join our free mailing list below to receive real-time news alerts and our next featured stock!
